Table 2 Summary of findings table
Outcomes | Anticipated absolute effects* (95% CI) | Relative effect (95% CI) | No. of participants (studies) | Certainty of the evidence (GRADE) | |
|---|---|---|---|---|---|
Risk with intermittent infusion | Risk with Prolonged infusion | ||||
All-cause mortality within 30 days | 287 per 1,000 | 235 per 1000 (201 to 276) | RR 0.82 (0.70 to 0.96) | 1762 (9 RCTs) | ⨁⨁◯◯ Low a,b |
Hospital mortality | 249 per 1,000 | 189 per 1000 (149 to 239) | RR 0.76 (0.60 to 0.96) | 965 (6 RCTs) | ⨁⨁⨁◯ Moderate a |
ICU mortality | 216 per 1,000 | 160 per 1000 (123 to 205) | RR 0.74 (0.57 to 0.95) | 1058 (6 RCTs) | ⨁⨁⨁◯ Moderate a |
90-day mortality | 361 per 1,000 | 353 per 1000 (303 to 415) | RR 0.98 (0.84 to 1.15) | 1039 (2 RCTs) | ⨁⨁⨁◯ Moderate a |
Clinical cure | 396 per 1,000 | 499 per 1000(439 to 566) | RR 1.26 (1.11 to 1.43) | 1115 (7 RCTs) | ⨁⨁⨁◯ Moderate a |
Emergence of resistance | 194 per 1,000 | 178 per 1000 (134 to 238) | RR 0.92 (0.69 to 1.23) | 766 (2 RCTs) | ⨁⨁⨁◯ Moderate a |
Duration of treatment | MD 0.39 lower (1.04 lower to 0.27 higher) | 1505 (6 RCTs) | ⨁⨁◯◯ Low a,c | ||
Length of ICU stay | MD 0.01 lower (0.85 lower to 0.82 higher) | 1582 (7 RCTs) | ⨁⨁◯◯ Low a,c | ||
Length of hospital stay | MD 1.05 higher (0.65 lower to 2.76 higher) | 1472 (5 RCTs) | ⨁⨁◯◯ Low a,c | ||